Eccogene Biotechnology of Shanghai completed a $14.6 million Series A round led by Sinopharm Capital The company, which was established in January 2018, focuses on new-generation small molecule novel drugs that meet clinical needs at an affordable cost. The company is led by Jingye Zhou, Co-founder and CEO, who previously worked at Lilly and GlaxoSmithKline. Eccogene has established its own drug R&D team, through it plans to use the services of CRO, CMO and clinical research platforms. More details....
Stock Symbols: (NYSE: LLY) (NYSE: GSK)
Share this with colleagues:
Original Article: Eccogene of Shanghai Completes $14.6 Million Funding Led by Sinopharm